Bharat Biotech, Biovet, Sapigen Biologix Signs Collaborative Research Agreemente with CSIR-IICT

Hyderabad, India 29th March 2021: Bharat Biotech International, Biovet, and Sapigen Biologix have signed a joint Master Collaborative Agreement (MCA) with CSIR-Indian Institute of Chemical Technology (CSIR-IICT) today, to collaborate on the development of novel platform technologies for Bio Therapeutics and vaccines to support the indigenous, affordable health care solutions for humans and animals. The collaborators will identify the mutually interesting projects to pursue under the agreement.
As a part of this MCA, the Industry collaborators shall provide necessary financial support to CSIR-IICT for developing key raw materials required by the collaborators, and also perform in-vitro and in vivo studies for further development of potential vaccine candidates and bio-therapeutics formulations to be designed by the collaborators. The broad-based MCA enables the partners to take up futuristic development activities in other related areas as well.
The MCA follows the contribution by CSIR-IICT during February 2021, in developing a synthetic process route for adjuvant molecule TLR 7/8 to BBIL for Covaxin, an indigenous vaccine rolled out by BBIL. The partners intend to strengthen the excellent working relationship between the two organizations, by conducting studies on futuristic vaccines, bio-therapeutic formulations, delivery strategies and also explore innovative solutions to the vaccination administration process.
The MCA was signed in presence of Dr Shekhar C Mande, DG CSIR and Dr. Krishna M. Ella, CMD, Bharat Biotech, by Dr. Krishna Mohan, Executive Director, Bharat Biotech, Dr. Jalachari Ella, Director, Biovet and Dr. Raches Ella, Director, Sapigen Biologix and Dr. S Chandrasekhar for CSIR-IICT.
Speaking on the occasion Dr Shekhar C Mande said that he is delighted about the collaboration as it would help realise India’s Aatmanirbhar Vision and contribute to disruptive technologies in the healthcare arena. The expertise of other CSIR labs will also be pooled in, if necessary, to take forward this vision.
Dr. Krishna Ella, said this is a big forward-thinking step, to explore future innovative solutions by design, and developing novel vaccine platforms in association with Publicly-funded Institutions like CSIR-IICT, by pushing the boundaries of the advanced technologies. We look forward to fortifying this collaboration and strengthening the innovation ecosystem of human and animal Life Sciences.
Dr. Srivari Chandrasekhar said that CSIR-IICT will always be at the fore-front to collaborate with the biotech industry by providing them timely support, in their endeavor to contribute to the National demand for vaccines and bio-therapeutics.  CSIR-IICT has mechanisms in place to deliver under dire uncertainties like the present pandemic situation, and this preparedness is exemplified in the development of synthetic processes of key adjuvants necessary for Covaxin in a short span of 2 to 3 months.
About Bharat Biotech
Bharat Biotech has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of more than 16 vaccines, 4 bio-therapeutics, registrations in more than 123 countries, and the World Health Organization (WHO) Prequalification. Located in Genome Valley in Hyderabad, India, a hub for the global biotech industry, Bharat Biotech has built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution.
Having delivered more than 4 billion doses of vaccines worldwide, Bharat Biotech continues to lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis, Rabies, Chikungunya, Zika, and the world’s first tetanus-toxoid conjugated vaccine for Typhoid. Bharat’s commitment to global social innovation programs and public-private partnerships resulted in introducing path-breaking WHO pre-qualified vaccines BIOPOLIO®?, ROTAVAC®?, and Typbar TCV®? combatting polio, rotavirus, typhoid infections, respectively. The acquisition of the rabies vaccine facility, Chiron Behring, from GlaxoSmithKline (GSK) has positioned Bharat Biotech as the world's largest rabies vaccine manufacturer.
To learn more about Bharat Biotech, visit To learn more about Bharat Biotech visit
About BioVet: Biovet a leader in animal vaccines, with a world class Foot and Mouth Disease vaccine production facility, located in Malur, Karnataka, the company is dedicated to produce animal health care products including veterinary biologicals, bio-vaccines and other related products for large animals, poultry and pet animals, and is deeply committed in developing and delivering high-quality vaccines to address diseases that afflict common livestock including FMD (A, O, Asia-1, HSBQ, Sheep Pox, New Castle, IBR, etc.,) at its BSL-4 containment facility.
About Sapigen Biologix:  SBPL is engaged in research, design, development of technical know-how in all kinds of work in the fields of Biology, Bio-technology, Bio-Chemistry and varieties of drugs pharmaceuticals, medical diagnostic kits, vaccines, anti-bodies and other industrial bio-products such as enzymes and gums and have necessary capability to manufacture at GMP level and market such product globally.

CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad was established in 1944, as a constituent laboratory of Council of Scientific and Industrial Research (CSIR), Government of India. Since its inception, CSIR-IICT focussed on the development of advanced, sustainable and affordable technologies. It is internationally recognised for its contributions to chemistry & chemical technology and is an ideal place for taking ideas to commercialization through state of the art research and development. The primary strength of CSIR-IICT is its rich pool of scientists, post docs and doctoral students and strong support infrastructure with well-established NABL accredited Analytical facility, GLP recognised animal house, kilo lab facility, pilot plants and USFDA approved NMR centre. CSIR-IICT has developed globally competitive and environmentally friendly technologies in agrochemicals, pharmaceuticals, homogeneous and heterogeneous catalysts, lipids, coal, ceramics, bio-fuel, polymers, and coatings, fine chemicals, organic intermediates, generic drugs, environment and clean energy. More than 150 technologies developed by CSIR-IICT are in commercial productions. For eg: Hydrazine hydrate (HH) technology transferred to Gujarat Alkali Chemicals Ltd., (GACL), Toluene derivatives technologies to Vinati Organics, AZT (azidothymidine) to Cipla for control of AIDS, Misoprostol to AVRA Labs and many crop protection chemicals by most of the pesticide manufacturers in India. The institute also contributed largely towards societal work i.e., drinking water, AGR technology for conversion of organic waste to energy, pheromone application technology for crop protection etc., Noteworthy to mention that CSIR-IICT contributed significantly in providing various technologies for the mitigation of Sars-CoV-2 virus that include repurposed drugs, adjuvants for vaccines, masks, sanitisers, etc. Hence, the institute is the reliable destination for chemical and biotech industries.

Bharat Biotech International, Biovet, and Sapigen Biologix have signed a joint Master Collaborative Agreement (MCA) with CSIR-Indian Institute of Chemical Technology (CSIR-IICT) today, to collaborate on the development of novel platform technologies for Bio Therapeutics and vaccines to support the indigenous, affordable health care solutions for humans and animals

Recommended News